133 Long-term safety and efficacy of elexacaftor-tezacaftor-ivacaftor in children aged 6 and older with cystic fibrosis and at least one F508del allele: 144-week results of an open-label extension study. - Wainwright, C.; McColley, S.; McNally, P.; Powers, M.; Ratjen, F.; Rayment, J.; Retsch-Bogart, G.; Roesch, E.; Ahluwalia, N.; Chu, C.; Menon, P.; Weinstock, T.; et al. (Journal of Cystic Fibrosis, 2023)